Sandy Srinivas

22.8k total citations · 3 hit papers
192 papers, 6.6k citations indexed

About

Sandy Srinivas is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Sandy Srinivas has authored 192 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Pulmonary and Respiratory Medicine, 76 papers in Surgery and 68 papers in Oncology. Recurrent topics in Sandy Srinivas's work include Renal cell carcinoma treatment (74 papers), Bladder and Urothelial Cancer Treatments (68 papers) and Prostate Cancer Treatment and Research (43 papers). Sandy Srinivas is often cited by papers focused on Renal cell carcinoma treatment (74 papers), Bladder and Urothelial Cancer Treatments (68 papers) and Prostate Cancer Treatment and Research (43 papers). Sandy Srinivas collaborates with scholars based in United States, Canada and South Korea. Sandy Srinivas's co-authors include Toni K. Choueiri, Ulka N. Vaishampayan, Lauren C. Harshman, Sumanta K. Pal, Jae‐Lyun Lee, Brian I. Rini, Daniel Y.C. Heng, Lori Wood, Frede Donskov and Sun Young Rha and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Sandy Srinivas

186 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

2017 664 citations Terence W. Friedlander, Christopher Hoimes et al. profile →
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

2022 163 citations Christopher Hoimes, Thomas W. Flaig et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandy Srinivas United States	40	3.4k	2.9k	2.2k	2.0k	1.2k	192	6.6k
Aristotelis Bamias Greece	36	2.2k 0.7×	3.1k 1.0×	1.9k 0.9×	1.7k 0.8×	829 0.7×	276	6.9k
Rana R. McKay United States	36	3.0k 0.9×	2.3k 0.8×	1.0k 0.5×	1.3k 0.7×	1.2k 1.0×	416	5.0k
Philippe Beuzeboc France	47	3.2k 0.9×	3.9k 1.3×	1.6k 0.7×	1.2k 0.6×	2.4k 1.9×	243	7.6k
Maciej Krzakowski Poland	43	6.4k 1.9×	7.6k 2.6×	944 0.4×	2.2k 1.1×	1.6k 1.3×	261	11.4k
Robert Dreicer United States	48	2.9k 0.8×	3.3k 1.1×	3.8k 1.8×	2.3k 1.2×	1.2k 0.9×	179	8.3k
Louis Lacombe Canada	39	3.0k 0.9×	3.4k 1.2×	2.7k 1.2×	1.6k 0.8×	855 0.7×	179	7.2k
Janine Mansi United Kingdom	41	2.3k 0.7×	3.5k 1.2×	998 0.5×	1.0k 0.5×	1.2k 0.9×	123	6.5k
Roger von Moos Switzerland	41	1.9k 0.5×	4.2k 1.4×	1.1k 0.5×	1.4k 0.7×	668 0.5×	234	6.2k
Yan‐Ping Mao China	44	1.8k 0.5×	2.5k 0.8×	2.3k 1.1×	1.0k 0.5×	1.1k 0.9×	203	6.4k
Anders Jakobsen Denmark	50	2.5k 0.7×	4.6k 1.6×	3.1k 1.4×	2.2k 1.1×	2.6k 2.1×	378	9.6k

Countries citing papers authored by Sandy Srinivas

Since Specialization

Citations

This map shows the geographic impact of Sandy Srinivas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandy Srinivas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandy Srinivas more than expected).

Fields of papers citing papers by Sandy Srinivas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandy Srinivas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandy Srinivas. The network helps show where Sandy Srinivas may publish in the future.

Co-authorship network of co-authors of Sandy Srinivas

This figure shows the co-authorship network connecting the top 25 collaborators of Sandy Srinivas. A scholar is included among the top collaborators of Sandy Srinivas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandy Srinivas. Sandy Srinivas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rivero, Jaydira Del, Tobias Else, Julie Hallanger‐Johnson, et al.. (2024). A review of mitotane in the management of adrenocortical cancer. The Oncologist. 29(9). 747–760. 5 indexed citations

Song, Hong, Valentina Ferri, Heying Duan, et al.. (2024). Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of ¹⁷⁷Lu-PSMA-617 treatment.. Journal of Clinical Oncology. 42(4_suppl). 32–32. 1 indexed citations

Hui, Gavin, Yen Low, Saurabh Gombar, et al.. (2024). Real world evidence comparison of first-line (1L) immune-oncology(IO)/tyrosine kinase inhibitor (TKI) vs. IO/IO combination therapy in renal cell carcinoma (RCC).. Journal of Clinical Oncology. 42(4_suppl). 402–402. 1 indexed citations

Song, Hong, Valentina Ferri, Heying Duan, et al.. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 51(9). 2784–2793. 10 indexed citations

Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2023). A Plain Language Summary Exploring a New Treatment Combination for Untreated Locally Advanced or Metastatic Urothelial Cancer: Enfortumab Vedotin Plus Pembrolizumab. Future Oncology. 20(7). 351–360. 3 indexed citations

Zhu, Han, Francisco X. Galdos, Daniel Lee, et al.. (2022). Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis. Circulation. 146(4). 316–335. 103 indexed citations

Hoimes, Christopher, Thomas W. Flaig, Matthew I. Milowsky, et al.. (2022). Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer. Journal of Clinical Oncology. 41(1). 22–31. 163 indexed citations breakdown →

Bhindi, Bimal, Jeffrey Graham, J. Connor Wells, et al.. (2020). Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology. 78(4). 615–623. 42 indexed citations

Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049. 223 indexed citations breakdown →

10.

Tripathi, Abhishek, Jeffrey G. Supko, Kathryn P. Gray, et al.. (2020). Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research. 26(23). 6122–6131. 13 indexed citations

11.

Waliany, Sarah, Kristin L. Sainani, Lesley S. Park, et al.. (2019). Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC CardioOncology. 1(1). 24–36. 44 indexed citations

12.

DeRouen, Mindy C., Mahasin S. Mujahid, Sandy Srinivas, & Theresa H.M. Keegan. (2015). Disparities in Adolescent and Young Adult Survival After Testicular Cancer Vary by Histologic Subtype: A Population-Based Study in California 1988–2010. Journal of Adolescent and Young Adult Oncology. 5(1). 31–40. 28 indexed citations

13.

Alimohamed, Nimira, Sandy Srinivas, Georg A. Bjarnason, et al.. (2014). A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 12(4). e127–e131. 27 indexed citations

14.

Harshman, Lauren C., et al.. (2013). A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 11(2). 100–106. 23 indexed citations

15.

Hall, Philip S., Lauren C. Harshman, Sandy Srinivas, & Ronald Witteles. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC Heart Failure. 1(1). 72–78. 155 indexed citations

16.

Ryan, Charles J., Mark Rosenthal, Siobhan Ng, et al.. (2012). Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. Clinical Cancer Research. 19(1). 215–224. 64 indexed citations

17.

Srinivas, Sandy & David Feldman. (2009). A phase II trial of calcitriol and naproxen in recurrent prostate cancer.. PubMed. 29(9). 3605–10. 53 indexed citations

18.

Srinivas, Sandy, et al.. (2008). Accuracy of references in general surgical journals — An old problem revisited. The Surgeon. 6(2). 71–75. 33 indexed citations

19.

Gralow, Julie R., J. Sybil Biermann, Azeez Farooki, et al.. (2007). NCCN task force report. Journal of the National Comprehensive Cancer Network. 9. 32 indexed citations

20.

Srinivas, Sandy, Aruna V. Krishnan, Natalia Colocci, & David Feldman. (2006). Phase II study evaluating oral triamcinolone in patients with androgen-independent prostate cancer. Urology. 67(5). 1001–1006. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact